Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70 and can sign the consent form
- Your breast cancer is HER2-negative and locally advanced or metastatic, confirmed by lab tests
- You have already had at least 2 different treatment lines, including taxane and/or anthracycline, or hormone therapy that has stopped working
- You must have ECOG 0–2 and be expected to live at least 3 months
- There must be at least one measurable tumor spot on scans (evaluable lesion)
- Blood, liver, and kidney tests must be good enough, and prior treatment side effects must be mostly gone (to Grade 1 or better)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
This trial studies whether adding bevacizumab (an anti-blood-vessel medicine) to chemotherapy before surgery improves treatment outcomes for people with HER2-negative breast cancer. It’s mainly for tumors that are stage II to IIIC and have not had prior cancer treatment.
This trial compares an oral capsule form of the experimental drug Utidelone with the standard injection form, in people with HER2-negative advanced breast cancer. The goal is to see if the capsule works as well as the injection and is safe to use.
This trial tests a new chemotherapy drug called utidelone, given before surgery for early high-risk or locally advanced breast cancer. The goal is to see if this drug can shrink tumors and improve outcomes. It may be a treatment option for people who meet the specific criteria.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.